Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
Participants treated with TransCon PTH also achieved normal mean serum calcium, serum phosphate, and urine calcium, and demonstrated improved HRQoL over 26 weeks of treatment.( 13 ) The primary objective of the phase 3, randomized, double‐blind, placebo‐controlled PaTHway trial was to assess the treatment effect of once‐daily TransCon PTH on serum calcium levels and therapeutic doses of active vitamin D (ie, calcitriol or alfacalcidol) and elemental calcium in adults with hypoparathyroidism over 26 weeks.
Source: Introduction. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
PaTHway is a phase 3, multicenter (North America and Europe), randomized, double‐blind, placebo‐controlled, parallel‐group, 26‐week trial with an open‐label extension of 156 weeks that evaluated the efficacy, safety, and tolerability of once‐daily TransCon PTH as PTH replacement therapy in individuals with hypoparathyroidism.
Source: Methods.
To ensure safety for those who might be randomized to the placebo arm, participants were required to achieve an albumin‐adjusted or ionized serum calcium within the normal range or slightly below the normal range (albumin‐adjusted serum calcium 7.8 to 10.6 mg/dL [1.95 to 2.64 mmol/L] or ionized serum calcium 4.40 to 5.29 mg/dL [1.10 to 1.32 mmol/L]), 25(OH) vitamin D levels 20 to 80 ng/mL (49 to 200 nmol/L), and magnesium levels ≥1.3 mg/dL (0.53 mmol/L), as is currently the goal of conventional treatment.( ) Urinary calcium excretion ≥125 mg/24 h and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 was required for enrollment.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26‐Week Results From the Phase 3 PaTHway Trial
Study design awaiting verification · Journal of Bone and Mineral Research · 2022
Original publication title
Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26‐Week Results From the Phase 3 PaTHway Trial
© 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
ABSTRACT
Conventional therapy for hypoparathyroidism consisting of active vitamin D and calcium aims to alleviate hypocalcemia but fails to restore normal parathyroid hormone (PTH) physiology. PTH replacement therapy is the ideal physiologic treatment for hypoparathyroidism. The double‐blind, placebo‐controlled, 26‐week, phase 3 PaTHway trial assessed the efficacy and safety of PTH replacement therapy for hypoparathyroidism individuals with the investigational drug TransCon PTH (palopegteriparatide). Participants (n = 84) were randomized 3:1 to once‐daily TransCon PTH (initially 18 μg/d) or placebo, both co‐administered with conventional therapy.
The study drug and conventional therapy were titrated according to a dosing algorithm guided by serum calcium. The composite primary efficacy endpoint was the proportion of participants at week 26 who achieved normal albumin‐adjusted serum calcium levels (8.3 to 10.6 mg/dL), independence from conventional therapy (requiring no active vitamin D and ≤600 mg/d of calcium), and no increase in study drug over 4 weeks before week 26. Other outcomes of interest included health‐related quality of life measured by the 36‐Item Short Form Survey (SF‐36), hypoparathyroidism‐related symptoms, functioning, and well‐being measured by the Hypoparathyroidism Patient Experience Scale (HPES), and urinary calcium excretion.
At week 26, 79% (48/61) of participants treated with TransCon PTH versus 5% (1/21) wiplacebo met the composite primary efficacy endpoint (p < 0.0001). TransCon PTH treatment demonstrated a significant improvement in all key secondary endpoint HPES domain scores (all p < 0.01) and the SF‐36 Physical Functioning subscale score (p = 0.0347) compared with placebo. Additionally, 93% (57/61) of participants treated with TransCon PTH achieved independence from conventional therapy. TransCon PTH treatment normalized mean 24‐hour urine calcium.
Overall, 82% (50/61) treated with TransCon PTH and 100% (21/21) wiplacebo experienced adverse events; most were mild (46%) or moderate (46%). No study drug‐related withdrawals occurred. In conclusion, TransCon PTH maintained normocalcemia while permitting independence from conventional therapy and was well‐tolerated in individuals with hypoparathyroidism. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Authors’ abstract
ABSTRACT
Conventional therapy for hypoparathyroidism consisting of active vitamin D and calcium aims to alleviate hypocalcemia but fails to restore normal parathyroid hormone (PTH) physiology. PTH replacement therapy is the ideal physiologic treatment for hypoparathyroidism. The double‐blind, placebo‐controlled, 26‐week, phase 3 PaTHway trial assessed the efficacy and safety of PTH replacement therapy for hypoparathyroidism individuals with the investigational drug TransCon PTH (palopegteriparatide). Participants (n = 84) were randomized 3:1 to once‐daily TransCon PTH (initially 18 μg/d) or placebo, both co‐administered with conventional therapy.
The study drug and conventional therapy were titrated according to a dosing algorithm guided by serum calcium. The composite primary efficacy endpoint was the proportion of participants at week 26 who achieved normal albumin‐adjusted serum calcium levels (8.3 to 10.6 mg/dL), independence from conventional therapy (requiring no active vitamin D and ≤600 mg/d of calcium), and no increase in study drug over 4 weeks before week 26. Other outcomes of interest included health‐related quality of life measured by the 36‐Item Short Form Survey (SF‐36), hypoparathyroidism‐related symptoms, functioning, and well‐being measured by the Hypoparathyroidism Patient Experience Scale (HPES), and urinary calcium excretion.
At week 26, 79% (48/61) of participants treated with TransCon PTH versus 5% (1/21) wiplacebo met the composite primary efficacy endpoint (p < 0.0001). TransCon PTH treatment demonstrated a significant improvement in all key secondary endpoint HPES domain scores (all p < 0.01) and the SF‐36 Physical Functioning subscale score (p = 0.0347) compared with placebo. Additionally, 93% (57/61) of participants treated with TransCon PTH achieved independence from conventional therapy. TransCon PTH treatment normalized mean 24‐hour urine calcium.
Overall, 82% (50/61) treated with TransCon PTH and 100% (21/21) wiplacebo experienced adverse events; most were mild (46%) or moderate (46%). No study drug‐related withdrawals occurred. In conclusion, TransCon PTH maintained normocalcemia while permitting independence from conventional therapy and was well‐tolerated in individuals with hypoparathyroidism. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Publication and source details
Original title: Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26‐Week Results From the Phase 3 PaTHway Trial
Aliya A Khan; Mishaela R Rubin; Peter Schwarz; Tamara Vokes; Dolores M Shoback; Claudia Gagnon; Andrea Palermo; Claudio Marcocci; Bart L Clarke; Lisa G Abbott; Lorenz C Hofbauer; Lynn Kohlmeier; Susanne Pihl; Xuebei An; Walter Frank Eng; Alden R Smith; Jenny Ukena; Christopher T Sibley; Aimee D Shu; Lars Rejnmark
Journal of Bone and Mineral Research · 2022
* Address correspondence to: Aliya A Khan, MD, Endocrinology, Metabolism, and Geriatrics, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada. E‐mail: draliyakhan@gmail.com© 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Ascendis Pharma Bone Diseases A/S, Hellerup, Denmark
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T08:16:55.447324+00:00
DOI: 10.1002/jbmr.4726 · PMC10099823